Compare JSPR & XCUR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | JSPR | XCUR |
|---|---|---|
| Founded | 2018 | 2011 |
| Country | United States | United States |
| Employees | 22 | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 14.9M | 13.7M |
| IPO Year | N/A | 2017 |
| Metric | JSPR | XCUR |
|---|---|---|
| Price | $0.43 | $1.96 |
| Analyst Decision | Buy | |
| Analyst Count | 11 | 0 |
| Target Price | ★ $15.50 | N/A |
| AVG Volume (30 Days) | ★ 500.9K | 37.9K |
| Earning Date | 05-12-2026 | 03-25-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 83.37 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.32 | $1.71 |
| 52 Week High | $4.00 | $9.50 |
| Indicator | JSPR | XCUR |
|---|---|---|
| Relative Strength Index (RSI) | 38.25 | 30.09 |
| Support Level | $0.42 | $1.71 |
| Resistance Level | $0.60 | $3.40 |
| Average True Range (ATR) | 0.07 | 0.41 |
| MACD | 0.01 | -0.05 |
| Stochastic Oscillator | 39.73 | 13.42 |
Jasper Therapeutics Inc is a clinical-stage biotechnology company focused on developing therapeutics targeting mast cell driven diseases such as Chronic Spontaneous Urticaria (CSU), Chronic Inducible Urticaria (CIndU) and asthma. The company's lead product candidate, briquilimab, is a monoclonal antibody designed to block stem cell factor (SCF) from binding to and signaling through the CD117 (KIT) receptor on mast and stem cells. The company has a single operating and reportable segment, which is the research and development of therapeutic products in the fields of chronic urticaria and asthma.
Exicure Inc is a clinical-stage biotechnology company focused on developing treatments for blood-related diseases, with an emphasis on small-molecule therapies that have the potential to benefit a broad range of patients. The company acquired GPCR Therapeutics USA and secured a license for GPC-100 (Burixafor), a clinical-stage small-molecule compound that inhibits the chemokine receptor CXCR4. GPC-100 has demonstrated the ability to effectively mobilize various cell types, including hematopoietic stem cells and lymphocytes, highlighting its broad therapeutic potential across multiple indications.